Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
291.64
+6.41 (2.25%)
May 22 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 285.17 - 292.96
52 week 116.01 - 292.96
Open 286.70
Vol / Avg. 393,502.00/70,923.00
Mkt cap 99.41B
P/E 80.91
Div/yield     -
EPS 3.60
Shares 342.27M
Beta 0.34
Inst. own 83%
Jul 29, 2015
Q2 2015 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 20, 2015
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
May 19, 2015
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting - Webcast
Apr 29, 2015
Q1 2015 Valeant Pharmaceuticals International Inc Earnings Release
Apr 29, 2015
Q1 2015 Valeant Pharmaceuticals International Inc Earnings Call
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 3.40% 11.04%
Operating margin 23.89% 23.11%
EBITD margin - 55.83%
Return on average assets 0.92% 3.36%
Return on average equity 5.03% 17.52%
Employees 16,800 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 55
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Age: 53
Pavel Mirovsky President and General Manager, Europe
Age: 64
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Ari Kellen Executive Vice President, Company Group Chairman
Age: 51
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 39
Robert A. Ingram Lead Independent Director
Age: 72
Ronald Harold Farmer Independent Director
Age: 64
Colleen A. Goggins Independent Director
Age: 60